Key insight: A letter in Nature Methods noting flaws in the CRISPR gene editing system spooked investors today, but it shouldn’t have — because we’ve long known about those problems.
A letter in Nature Methods pointing out potentially dangerous flaws in the CRISPR-Cas9 genome editing system gave biotech investors a sinking feeling on Tuesday, and stocks in genome-editing companies had the same experience. By the close of trading Editas Medicine had fallen nearly 12 percent, Crispr Therapeutics was down more than 5 percent, and Intellia Therapeutics had plunged just over 14 percent.
But the truth was, the concerns outlined in the letter were hardly new.
About the Author Reprints
